Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
Isatuximab, Bortezomib, Dexamethasone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Not listed No phase listed Observational Accepts healthy volunteers

A Proof of Concept Top Evaluate a Novel Penile Lengthening Protocol

NCT04231422
Conditions
Penile Elongation
Interventions
Platelet-rich plasma
Combination Product
Lead sponsor
Judson Brandeis
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Ramon, California
Conditions
Tennis Elbow
Interventions
Dextrose prolotherapy, PrT-DMS, Platelet Rich Plasma injection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Madison, Wisconsin
Conditions
Leukemia, Lymphoma, Myeloma
Interventions
Rituximab, Cyclophosphamide, Fludarabine, Mesna, Radiation Treatment, Stem Cell Transplantation (SCT), Sirolimus, Anti-third Party Cytolytic T-lymphocytes (CTL)
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Not listed No phase listed Observational Accepts healthy volunteers

Etiology of Multiple Myeloma: A Case-Control Study

NCT00505999
Conditions
Multiple Myeloma
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
Convalescent Plasma, Saline solution
Biological · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
New Haven, Connecticut • Miami, Florida • New York, New York + 5 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ravuconazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Knee Osteoarthritis
Interventions
Platelet Rich Plasma, Normal Saline
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Multiple Myeloma
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
21
States / cities
Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
Conditions
Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions
management of therapy complications, pain therapy
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Pembrolizumab
Biological
Lead sponsor
Alfred Chung, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders, Hematologic Diseases
Interventions
Campath, Busulfan, Fludarabine, Hematopoietic stem cell infusion, FK-506
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Conditions
B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Splenic Marginal Zone Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
Interventions
alvocidib, fludarabine phosphate, rituximab, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Acute Burns
Interventions
Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care
Device · Other
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 86 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah
Conditions
Non-healing Wound
Interventions
Platelet Rich Plasma
Other
Lead sponsor
St Elizabeth Healthcare
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Edgewood, Kentucky
Conditions
Relapsed/Refractory Myeloma
Interventions
Fludarabine phosphate, Cyclophosphamide, Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Indolent Non-Hodgkin's Lymphomas
Interventions
Placebo, Rituximab, Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Chandler, Arizona • Duarte, California + 28 more
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
prednisone, thalidomide
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
16 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Conditions
Indolent Lymphomas, Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, Cutaneous T Cell Lymphoma
Interventions
Exercise, Diet
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
amphotericin B deoxycholate, nystatin
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri